ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA

doi:10.3748/wjg.v23.i10.1796

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7358)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

416

WORD

289

HTML

3351

Figures (1-6)

346

Sum=4402

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

959

Download

1997

Sum=2956

Mar 14, 2017 (publication date) through Jan 23, 2025

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Mar 14, 2017; 23(10): 1796-1803
Published online Mar 14, 2017. doi: 10.3748/wjg.v23.i10.1796

Full Size Figure Download Figure

Figure 2 Survival rate at various concentrations of esophageal cancer-related gene 2. A dose- and time- dependent association between the survival rate of the EC9706/cisplatin (DDP) cells and the concentration of ECRG2. A longer incubation time with ECRG2 significantly decreased the survival rate of EC9706/DDP cells. The same was found for treatments with a higher concentration of ECRG2.

Citation: Hou XF, Xu LP, Song HY, Li S, Wu C, Wang JF. ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA. World J Gastroenterol 2017; 23(10): 1796-1803
URL: https://www.wjgnet.com/1007-9327/full/v23/i10/1796.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i10.1796